Vasodilator use linked to AMD development

Article

Taking vasodilators may increase the risk of developing early-stage age-related macular degeneration (AMD), according to a study published online.

Taking vasodilators may increase the risk of developing early-stage age-related macular degeneration (AMD), according to a study published online in Ophthalmology.

Researchers from the University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA, conducted a long-term population-based cohort study from 1988 to 2013 of nearly 5000 residents of Beaver Dam, Wisconsin, USA, aged 43 to 86 years. The research is part of the Beaver Dam Eye Study, which since 1987 has collected information on the prevalence and incidence of macular degeneration and diabetic retinopathy.

The researchers found that, after adjusting for age, sex and other factors, using any vasodilator was associated with a 72% greater risk of developing early-stage AMD. Among people who were not taking vasodilators, about 8% developed signs of early AMD. In comparison, among those taking a vasodilator medication, about 19% developed the disease.

The researchers also found that taking oral beta blockers was associated with a 71% increase in the risk of neovascular AMD. Among those who were not taking oral beta blockers, only 0.5% developed signs of neovascular AMD, compared to 1.2% of those taking oral beta blockers.

The researchers caution that their study was not able to discern effects of the medications themselves and the conditions for which participants were taking those medications.

"As significant as these results may be, it's important that they be replicated first, and if possible tested in a clinical trials setting before changing anyone's medication regimens," said Dr Ronald Klein, MPH, lead researcher of the study. "Further research is needed to determine the cause of these increased risks."

To read the abstract of the study, visit the journal's website.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.